Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis

Detalhes bibliográficos
Autor(a) principal: Innominato, P
Data de Publicação: 2022
Outros Autores: Cailliez, V, Allard, MA, Lopez-Ben, S, Ferrero, A, Pinto Marques, H, Hubert, C, Giuliante, F, Pereira, F, Cugat, E, Mirza, D, Costa-Maia, J, Serrablo, A, Lapointe, R, Dopazo, C, Tralhao, J, Kaiser, G, Chen, JS, Garcia-Borobia, F, Regimbeau, JM, Skipenko, O, Lin, JK, Laurent, C, Opocher, E, Goto, Y, Chibaudel, B, de Gramont, A, Adam, R
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.17/4757
Resumo: Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes.
id RCAP_c0532f902737688850e4561edff4285b
oai_identifier_str oai:repositorio.chlc.min-saude.pt:10400.17/4757
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey AnalysisHCC CIRLiverMetSurveyColorectal CancerDownsizingHepatectomyIrresectable Hepatic MetastasesLiver MetastasesLiver ResectionNeo-Adjuvant ChemotherapyOnco-Surgical ApproachPreoperative ChemotherapyReal-World EvidenceBackground: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes.MDPIRepositório do Centro Hospitalar Universitário de Lisboa Central, EPEInnominato, PCailliez, VAllard, MALopez-Ben, SFerrero, APinto Marques, HHubert, CGiuliante, FPereira, FCugat, EMirza, DCosta-Maia, JSerrablo, ALapointe, RDopazo, CTralhao, JKaiser, GChen, JSGarcia-Borobia, FRegimbeau, JMSkipenko, OLin, JKLaurent, COpocher, EGoto, YChibaudel, Bde Gramont, AAdam, R2023-12-05T15:45:35Z2022-092022-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.17/4757engCancers (Basel) . 2022 Sep 5;14(17):4340.10.3390/cancers14174340info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-10T05:41:47Zoai:repositorio.chlc.min-saude.pt:10400.17/4757Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:42:09.070818Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
spellingShingle Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
Innominato, P
HCC CIR
LiverMetSurvey
Colorectal Cancer
Downsizing
Hepatectomy
Irresectable Hepatic Metastases
Liver Metastases
Liver Resection
Neo-Adjuvant Chemotherapy
Onco-Surgical Approach
Preoperative Chemotherapy
Real-World Evidence
title_short Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_full Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_fullStr Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_full_unstemmed Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
title_sort Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
author Innominato, P
author_facet Innominato, P
Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Pinto Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, D
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
author_role author
author2 Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Pinto Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, D
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Centro Hospitalar Universitário de Lisboa Central, EPE
dc.contributor.author.fl_str_mv Innominato, P
Cailliez, V
Allard, MA
Lopez-Ben, S
Ferrero, A
Pinto Marques, H
Hubert, C
Giuliante, F
Pereira, F
Cugat, E
Mirza, D
Costa-Maia, J
Serrablo, A
Lapointe, R
Dopazo, C
Tralhao, J
Kaiser, G
Chen, JS
Garcia-Borobia, F
Regimbeau, JM
Skipenko, O
Lin, JK
Laurent, C
Opocher, E
Goto, Y
Chibaudel, B
de Gramont, A
Adam, R
dc.subject.por.fl_str_mv HCC CIR
LiverMetSurvey
Colorectal Cancer
Downsizing
Hepatectomy
Irresectable Hepatic Metastases
Liver Metastases
Liver Resection
Neo-Adjuvant Chemotherapy
Onco-Surgical Approach
Preoperative Chemotherapy
Real-World Evidence
topic HCC CIR
LiverMetSurvey
Colorectal Cancer
Downsizing
Hepatectomy
Irresectable Hepatic Metastases
Liver Metastases
Liver Resection
Neo-Adjuvant Chemotherapy
Onco-Surgical Approach
Preoperative Chemotherapy
Real-World Evidence
description Background: Prognostic factors have been extensively reported after resection of colorectal liver metastases (CLM); however, specific analyses of the impact of preoperative systemic anticancer therapy (PO-SACT) features on outcomes is lacking. Methods: For this real-world evidence study, we used prospectively collected data within the international surgical LiverMetSurvey database from all patients with initially-irresectable CLM. The main outcome was Overall Survival (OS) after surgery. Disease-free (DFS) and hepatic-specific relapse-free survival (HS-RFS) were secondary outcomes. PO-SACT features included duration (cumulative number of cycles), choice of the cytotoxic backbone (oxaliplatin- or irinotecan-based), fluoropyrimidine (infusional or oral) and addition or not of targeted monoclonal antibodies (anti-EGFR or anti-VEGF). Results: A total of 2793 patients in the database had received PO-SACT for initially irresectable diseases. Short (<7 or <13 cycles in 1st or 2nd line) PO-SACT duration was independently associated with longer OS (HR: 0.85 p = 0.046), DFS (HR: 0.81; p = 0.016) and HS-RFS (HR: 0.80; p = 0.05). All other PO-SACT features yielded basically comparable results. Conclusions: In this international cohort, provided that PO-SACT allowed conversion to resectability in initially irresectable CLM, surgery performed as soon as technically feasible resulted in the best outcomes. When resection was achieved, our findings indicate that the choice of PO-SACT regimen had a marginal if any, impact on outcomes.
publishDate 2022
dc.date.none.fl_str_mv 2022-09
2022-09-01T00:00:00Z
2023-12-05T15:45:35Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.17/4757
url http://hdl.handle.net/10400.17/4757
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cancers (Basel) . 2022 Sep 5;14(17):4340.
10.3390/cancers14174340
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136323367337984